Page 7 - Dr Reddy’s Laboratories

Covid-19: Govt waives import duty on Remdesivir injection, raw materials

Given the shortage of supplies, the Union government last week banned the export of Remdesivir

Dr Reddy's to also use govt cold chain infra for Sputnik V distribution

The vaccine would be transported in frozen form by air and road

Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh

Access to the private market, international sales are other factors that will impact margins

India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V

Final nod from DCGI soon, jab likely at $3/dose

Dr Reddys surges 5% as Sputnik V gets expert panel nod for emergency use

This is the third vaccine approved by India, after Covishield and Covaxin.

India drug regulator asks Dr. Reddy's for more data on Sputnik V vaccine

An expert panel of India's drug regulator sought additional data from drugmaker Dr Reddy's on its Sputnik V Covid-19 vaccine trial, in its second such request after an initial evaluation in February

Expert panel defers decision on Sputnik V Covid-19 vaccine, wants more data

Details of -25°C cold chain plan sought

No Sputnik V approval yet, SEC asks Dr Reddy's for more data on vax

The Subject Expert Committee (SEC) of the Indian drug regulator, tasked with vetting Covid-19 vaccine proposals, sought additional data on Russian Covid-19 vaccine 'Sputnik V'

Wait for Sputnik V Covid-19 vaccine may get over in a few weeks: DRL

"We expect to get the approval in the next few weeks," said Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL)

Dr Reddy's expects Covid vaccine to get nod from India in next few weeks

Pharma major Dr Reddy's Laboratories expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said

Stelis Biopharma to make 200 mn doses of Russia's Sputnik V Covid vaccine

Stelis will commence supplies from September quarter of 2021 and will also continue to work with RDIF to provide additional supply volumes beyond the initial agreement

Dr Reddy's Lab receives 3 observations for New York API manufacturing plant

The pharma firm said it will address all observations comprehensively within the stipulated timeline

Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection

Efficacy of a vaccine means its ability to stimulate immunity in a person who has received the shot

Expert panel asks DRL to come back with more data on Sputnik safety

DRL applied for restricted emergency use of Sputnik V last week, has lined up 250 mn doses for Indians over next 12 months

Dr Reddy's applies for emergency use approval for Sputnik V vaccine

Aims to launch the vaccine in March if regulator approval comes through

Lupin plans expansion, aims to enter Chinese market in the next one year

The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive

Dr Reddy's reports Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore

DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.

Dr Reddy's Laboratories likely to launch Sputnik V under EUA in March

The bridge trials on 1,600 participants in India was ongoing. The phase 2 trials are completed and the phase 3 is on.

Dr Reddy's, Zuventus get nod to conduct Covid-19 trials on repurposed drugs

NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.

Select large caps likely to give good returns in 2021, say analysts

With valuations at a premium, brokerages highlight the need for caution